Analysis of outcome according to risk factors in the randomized phase III TURANDOT trial evaluating first-line bevacizumab-containing therapy for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)

被引：1

作者：

Brodowicz, T.

Pienkowski, T.

Beslija, S.

Melichar, B.

Lang, I.

Inbar, M. J.

Anghel, R.

Spanik, S.

Ahlers, S.

Zielinski, C.

机构：

[1] Med Univ Vienna, Vienna, Austria

[2] CECOG, Vienna, Austria

[3] Postgrad Med Ctr, Warsaw, Poland

[4] Inst Oncol, Sarajevo, Bosnia & Herceg

[5] Palacky Univ, Sch Med, CR-77147 Olomouc, Czech Republic

[6] Teaching Hosp, Olomouc, Czech Republic

[7] Natl Inst Oncol, Budapest, Hungary

[8] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, IL-69978 Tel Aviv, Israel

[9] Univ Med & Pharm, Bucharest, Romania

[10] Onkol Ustav Sv Alzbety, Bratislava, Slovakia

[11] IST GmbH, Mannheim, Germany

来源：

关键词：

D O I：

10.1158/0008-5472.SABCS13-P6-06-40

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P6-06-40

引用

页数：2